NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. It targets wound healing and pain therapy, and can be administered at home, without the assistance of medical professionals. Its products include WoundShield, PainShield, and UroShield. It operates through the following geographical segments: United States, Israel, United Kingdom, European Union, India, and Other. The company was founded by Harold Jacob and Jona Zumeris in September 2003 and is headquartered in Melville, NY.
SHORT INTEREST
23.96K 09/13/19
P/E Current
-4.56
P/E Ratio (with extraordinary items)
-3.15
Average Recommendation: BUY
Average Target Price: 10.50
SHORT INTEREST
23.96K 09/13/19
P/E Current
-4.56
P/E Ratio (with extraordinary items)
-3.15
Average Recommendation: BUY
Average Target Price: 10.50
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.